NCI awards five-year, $13.3M grant for collaborative study on sequential combinations of targeted inhibitors, immunotherapies

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.

April 12, 2024

Vol.50 No.15

By Jacquelyn Cobb

NCI Director's Report

Rathmell: To improve funding outlook, we must reverse distrust in science

With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional efforts to collaborate and rebuild trust in science, NCI Director Kimryn Rathmell said.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

Health Equity

NCI creates Cancer Equity Leaders group to improve cancer health equity

To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn from communities and inform workforce development as well as outreach initiatives.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

NCI is lowering paylines for R01 grants for established and new investigators to the 10th percentile, down from the 12th percentile in FY23.

April 05, 2024

Vol.50 No.14

By Matthew Bin Han Ong

In Brief

NCI renews UChicago’s CCC designation

NCI renewed the University of Chicago Medicine Comprehensive Cancer Center’s “comprehensive” designation and continued grant support for another five years.

April 05, 2024

Vol.50 No.14

In Brief

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.

April 05, 2024

Vol.50 No.14

NCI awards five-year, $13.3M grant for collaborative study on sequential combinations of targeted inhibitors, immunotherapies

YOU MAY BE INTERESTED IN

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

Rathmell: To improve funding outlook, we must reverse distrust in science

NCI creates Cancer Equity Leaders group to improve cancer health equity

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

NCI renews UChicago’s CCC designation

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Renew today!

Subscriber content

Login